HRP20120331T1 - Postupak sprječavanja ili liječenja infekcije bakterijom m. tuberculosis - Google Patents

Postupak sprječavanja ili liječenja infekcije bakterijom m. tuberculosis Download PDF

Info

Publication number
HRP20120331T1
HRP20120331T1 HRP20120331TT HRP20120331T HRP20120331T1 HR P20120331 T1 HRP20120331 T1 HR P20120331T1 HR P20120331T T HRP20120331T T HR P20120331TT HR P20120331 T HRP20120331 T HR P20120331T HR P20120331 T1 HRP20120331 T1 HR P20120331T1
Authority
HR
Croatia
Prior art keywords
pharmaceutical preparation
preparation according
seq
fusion protein
mammal
Prior art date
Application number
HRP20120331TT
Other languages
English (en)
Croatian (hr)
Inventor
Coler Rhea
Lobet Yves
Reed Steven
Original Assignee
Glaxosmithkline Biologicals Sa
Infectious Disease Research Institute (Idri)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa, Infectious Disease Research Institute (Idri) filed Critical Glaxosmithkline Biologicals Sa
Publication of HRP20120331T1 publication Critical patent/HRP20120331T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HRP20120331TT 2005-04-29 2006-04-27 Postupak sprječavanja ili liječenja infekcije bakterijom m. tuberculosis HRP20120331T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67654905P 2005-04-29 2005-04-29
US77701706P 2006-02-27 2006-02-27
PCT/EP2006/004319 WO2006117240A2 (en) 2005-04-29 2006-04-27 Novel method for preventing or treating m tuberculosis infection

Publications (1)

Publication Number Publication Date
HRP20120331T1 true HRP20120331T1 (hr) 2012-05-31

Family

ID=36972897

Family Applications (3)

Application Number Title Priority Date Filing Date
HRP20120331TT HRP20120331T1 (hr) 2005-04-29 2006-04-27 Postupak sprječavanja ili liječenja infekcije bakterijom m. tuberculosis
HRP20141125TT HRP20141125T1 (hr) 2005-04-29 2014-11-19 Postupak sprjeäśavanja ili lijeäśenja infekcije bakterijom m. tuberculosis
HRP20141184TT HRP20141184T1 (en) 2005-04-29 2014-12-08 Novel method for preventing or treating m. tuberculosis infection

Family Applications After (2)

Application Number Title Priority Date Filing Date
HRP20141125TT HRP20141125T1 (hr) 2005-04-29 2014-11-19 Postupak sprjeäśavanja ili lijeäśenja infekcije bakterijom m. tuberculosis
HRP20141184TT HRP20141184T1 (en) 2005-04-29 2014-12-08 Novel method for preventing or treating m. tuberculosis infection

Country Status (24)

Country Link
US (6) US8470338B2 (enExample)
EP (3) EP1877426B1 (enExample)
JP (4) JP5164830B2 (enExample)
KR (4) KR20130110233A (enExample)
CN (3) CN101273055B (enExample)
AT (1) ATE543832T1 (enExample)
AU (1) AU2006243357B2 (enExample)
BR (1) BRPI0611347A2 (enExample)
CA (2) CA2607715C (enExample)
CY (1) CY1112851T1 (enExample)
DK (3) DK2457926T3 (enExample)
EA (1) EA012576B1 (enExample)
ES (3) ES2524572T3 (enExample)
HR (3) HRP20120331T1 (enExample)
IL (2) IL186654A (enExample)
MA (1) MA29678B1 (enExample)
NO (3) NO340766B1 (enExample)
NZ (1) NZ562729A (enExample)
PH (1) PH12013502449A1 (enExample)
PL (3) PL2457926T3 (enExample)
PT (3) PT2426141E (enExample)
SI (3) SI1877426T1 (enExample)
WO (1) WO2006117240A2 (enExample)
ZA (1) ZA200709209B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2426141E (pt) * 2005-04-29 2014-11-25 Glaxosmithkline Biolog Sa Método para prevenção ou tratamento de uma infecção por m. tuberculosis
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
WO2007106536A2 (en) * 2006-03-14 2007-09-20 Oregon Health & Science University Methods for producing an immune response to tuberculosis
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
CN103550764A (zh) * 2007-03-02 2014-02-05 葛兰素史密丝克莱恩生物有限公司 疫苗组合物及其在刺激免疫反应中的用途
US8394839B2 (en) * 2007-08-21 2013-03-12 Stc.Unm Rationally improved isoniazid and ethionamide derivatives and activity through selective isotopic substitution
US20110189217A1 (en) * 2008-06-26 2011-08-04 Barry Michael A Methods and materials for producing immune responses against polypeptides involved in antibiotic resistance
EP2315773B1 (en) 2008-07-25 2016-08-24 GlaxoSmithKline Biologicals S.A. Polypeptides, polynucleotides and compositions for use in the treatment of latent tubeculosis
HRP20181353T1 (hr) * 2008-07-25 2018-10-19 Glaxosmithkline Biologicals S.A. Tuberkulozni protein rv2386c, njegovi pripravci i upotreba
NO2315597T3 (enExample) 2008-07-25 2018-01-20
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
EP2421557B1 (en) 2009-04-24 2018-12-05 Statens Serum Institut A tuberculosis tb vaccine to prevent reactivation
LT2528621T (lt) 2010-01-27 2016-12-12 Glaxosmithkline Biologicals S.A. Modifikuoti tuberkuliozės antigenai
SG190937A1 (en) 2010-12-14 2013-07-31 Glaxosmithkline Biolog Sa Mycobacterium antigenic composition
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
BR112013017267B1 (pt) 2011-01-04 2021-06-22 Archivel Farma, Sl Formulação de lipossomas, suspensão e composição farmacêutica
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
US20140349320A1 (en) * 2011-12-15 2014-11-27 The Trustees Of The University Of Pennsylvania Using Adaptive Immunity to Detect Drug Resistance
IN2014MN01594A (enExample) 2012-01-12 2015-05-08 Archivel Farma Sl
EP4299138A3 (en) * 2012-08-03 2024-08-14 Access to Advanced Health Institute Compositions and methods for treating an active mycobacterium tuberculosis infection
GB2521573A (en) * 2012-09-27 2015-06-24 Chengdu Yongan Pharmaceutical Co; Ltd Modified BCG strains with reduced or eliminated activity of LSR2 and pharmaceutical composition comprising same
CN102994595B (zh) * 2012-11-30 2018-10-26 广州白云山拜迪生物医药有限公司 一种融合蛋白包涵体的制备方法
CN102993266B (zh) * 2012-11-30 2019-08-23 广州白云山拜迪生物医药有限公司 一种融合蛋白的纯化和复性方法
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
US10588980B2 (en) * 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US10335374B2 (en) 2014-12-04 2019-07-02 University System of Georgia, Valdosta State University Tablet composition for anti-tuberculosis antibiotics
US10672502B2 (en) * 2015-04-02 2020-06-02 Biodesy, Inc. Methods for determining protein structure using a surface-selective nonlinear optical technique
WO2016179231A1 (en) * 2015-05-04 2016-11-10 Board Of Trustees Of Michigan State University Compositions and methods for inhibiting bacterial growth
GB201513176D0 (en) * 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
CA3045952A1 (en) 2016-12-07 2018-06-14 Glaxosmithkline Biologicals Sa Novel process
WO2019178472A1 (en) * 2018-03-16 2019-09-19 Washington University In St. Louis Use of fatty acid oxidation inhibitors as antimicrobials
US11717519B2 (en) 2017-04-21 2023-08-08 Washington University In St. Louis Use of fatty acid oxidation inhibitors as antimicrobials
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
WO2022119899A1 (en) * 2020-12-02 2022-06-09 Shionogi & Co., Ltd. A medicament for treating mycobacterial infection characterized by combining a cytochrome bc1 inhibitor with clarithromycin or azithromycin
KR20240049802A (ko) * 2021-08-31 2024-04-17 비르 바이오테크놀로지, 인코포레이티드 결핵 백신
KR102534846B1 (ko) 2021-12-14 2023-05-19 재단법인 환동해산업연구원 결핵균에 항균 활성을 가지는 해조류 추출물
CN116162141B (zh) * 2022-11-30 2024-04-12 中国疾病预防控制中心传染病预防控制所 一种结核分枝杆菌抗原epcra013及其应用

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
CA1340522C (en) * 1987-03-10 1999-05-04 Heinz Dobeli Fusion proteins containing neighbouring histidines for improved purification
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
WO1989006280A1 (en) 1988-01-04 1989-07-13 E.I. Du Pont De Nemours And Company Multiple stage affinity process for isolation of specific cells from a cell mixture
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5215926A (en) 1988-06-03 1993-06-01 Cellpro, Inc. Procedure for designing efficient affinity cell separation processes
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
EP1001032A3 (en) 1989-08-18 2005-02-23 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
KR920007887B1 (ko) 1989-08-29 1992-09-18 스즈키 지도오샤 고오교오 가부시키가이샤 내연기관의 배기가스 정화장치
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
WO1991016116A1 (en) 1990-04-23 1991-10-31 Cellpro Incorporated Immunoselection device and method
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
DK0553288T3 (da) 1990-10-18 1997-12-29 Cellpro Inc Apparat og fremgangsmåde til udskillelse af partikler ved brug af en eftergivende beholder
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US6113914A (en) 1991-08-15 2000-09-05 Smithkline Beecham Biologicals (S.A.) Osp A proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
US5240856A (en) 1991-10-23 1993-08-31 Cellpro Incorporated Apparatus for cell separation
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
ATE155681T1 (de) 1992-05-18 1997-08-15 Minnesota Mining & Mfg Einrichtung zur transmucosalen wirkstoffabgabe
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
DE69418699T2 (de) 1993-01-11 1999-09-30 Dana-Farber Cancer Institute, Boston Induktion der antworten zytotoxischer t-lymphozyten
FR2702160B1 (fr) 1993-03-02 1995-06-02 Biovecteurs As Vecteurs particulaires synthétiques et procédé de préparation.
KR100310510B1 (ko) 1993-03-23 2002-07-04 장 스테판느 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
FR2704145B1 (fr) 1993-04-21 1995-07-21 Pasteur Institut Vecteur particulaire et composition pharmaceutique le contenant.
US5955077A (en) 1993-07-02 1999-09-21 Statens Seruminstitut Tuberculosis vaccine
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5551622A (en) 1994-07-13 1996-09-03 Yoon; Inbae Surgical stapler
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
FR2723849B1 (fr) 1994-08-31 1997-04-11 Biovector Therapeutics Sa Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP0832282A1 (en) 1995-06-02 1998-04-01 Incyte Pharmaceuticals, Inc. IMPROVED METHOD FOR OBTAINING FULL-LENGTH cDNA SEQUENCES
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US6290969B1 (en) 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
EP1203817B9 (en) 1995-09-01 2006-08-16 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
MX9801687A (es) 1995-09-01 1998-11-29 Corixa Corp Compuestos y metodos para el diagnostico de tuberculosis.
EP0871747A1 (en) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunostimulation mediated by gene-modified dendritic cells
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
CA2268036A1 (en) 1996-10-11 1998-04-23 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
WO1998016247A1 (en) 1996-10-11 1998-04-23 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US5655998A (en) 1996-12-03 1997-08-12 Yu; Chih-An Space walking exerciser
AU743114B2 (en) 1997-04-01 2002-01-17 Corixa Corporation Aqueous immunologic adjuvant compositions of monophosphoryl lipid A
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
BR9907691B1 (pt) 1998-02-05 2011-05-31 derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina.
BR9909472A (pt) 1998-04-07 2001-09-11 Corixa Corp Polipeptìdeo purificado, processo para prevenir tuberculose, e, composição farmacêutica
EP1229931A4 (en) 1999-10-07 2003-05-28 Corixa Corp FUSION PROTEINS FROM MYCOBACTERIUM TUBERCULOSIS
US7472098B2 (en) 2000-02-14 2008-12-30 Ubs Financial Services, Inc. System and method for execution of trades made pursuant to stock option and purchase plans
PT2133100E (pt) * 2000-06-20 2012-01-11 Corixa Corp Antigénio mtb32a de mycobacterium tuberculosis com um local activo inactivado e suas proteínas de fusão
US20030143240A1 (en) 2000-06-27 2003-07-31 Cabezon-Silva Teresa Elisa Virginia Prostase protein vaccine comprising derivatised thiol residues and methods for producing said antigen
WO2002072792A2 (en) 2001-03-13 2002-09-19 Corixa Corporation Heterologous fusion protein constructs comprising a leishmania antigen
CN101570594B (zh) 2002-02-14 2012-06-20 三井化学株式会社 聚酯树脂及聚酯制备用催化剂、用此催化剂制备聚酯树脂的方法
AU2003213118A1 (en) * 2002-02-15 2003-09-09 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
GB0411411D0 (en) 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
WO2006078760A1 (en) 2005-01-19 2006-07-27 Panduit Corp. Communication channels with suppression cores
PT2426141E (pt) * 2005-04-29 2014-11-25 Glaxosmithkline Biolog Sa Método para prevenção ou tratamento de uma infecção por m. tuberculosis
JP4468858B2 (ja) 2005-06-01 2010-05-26 オリンパスイメージング株式会社 データ符号化装置、データ符号化方法、プログラム
US7296798B2 (en) 2006-01-31 2007-11-20 Matt Overfield Gameboard, games played on board and methods of play requiring strategy and luck
EP2421557B1 (en) 2009-04-24 2018-12-05 Statens Serum Institut A tuberculosis tb vaccine to prevent reactivation
US8567987B2 (en) 2009-07-21 2013-10-29 Cooper Technologies Company Interfacing a light emitting diode (LED) module to a heat sink assembly, a light reflector and electrical circuits
SG190937A1 (en) 2010-12-14 2013-07-31 Glaxosmithkline Biolog Sa Mycobacterium antigenic composition
US9119754B2 (en) 2011-10-08 2015-09-01 Michael Dennis Mattress overlay system with positionally adjustable, lateral ramp-wedge bolster structure
US9051890B2 (en) 2013-10-28 2015-06-09 Ford Global Technologies, Llc Method for estimating charge air cooler condensation storage with an intake oxygen sensor
US9903268B2 (en) 2015-04-02 2018-02-27 Ford Global Technologies, Llc Internal combustion engine with two-stage supercharging capability and with exhaust-gas aftertreatment arrangement, and method for operating an internal combustion engine
US9810514B2 (en) 2015-09-08 2017-11-07 Deufol Sunman Inc. Ammunition carrier consumer package

Also Published As

Publication number Publication date
HRP20141125T1 (hr) 2015-01-02
WO2006117240A3 (en) 2007-01-18
KR20130110233A (ko) 2013-10-08
US20190307872A1 (en) 2019-10-10
NO340206B1 (no) 2017-03-20
NO20075201L (no) 2008-01-25
CA2821389A1 (en) 2006-11-09
EA200702081A1 (ru) 2008-04-28
CA2821389C (en) 2015-11-17
ES2524572T3 (es) 2014-12-10
JP5659207B2 (ja) 2015-01-28
EP1877426B1 (en) 2012-02-01
MA29678B1 (fr) 2008-08-01
PT2426141E (pt) 2014-11-25
JP2015057403A (ja) 2015-03-26
KR20150036658A (ko) 2015-04-07
US20190030154A1 (en) 2019-01-31
CN106390108B (zh) 2020-09-08
KR101352806B1 (ko) 2014-02-17
NO340766B1 (no) 2017-06-19
DK2457926T3 (da) 2015-01-05
EP2426141A2 (en) 2012-03-07
US20090123491A1 (en) 2009-05-14
US20170065696A9 (en) 2017-03-09
US20140050776A1 (en) 2014-02-20
JP2012065650A (ja) 2012-04-05
EP2457926A1 (en) 2012-05-30
CN106390108A (zh) 2017-02-15
ZA200709209B (en) 2009-12-30
PL2426141T3 (pl) 2015-02-27
EP2426141A3 (en) 2012-08-15
CA2607715A1 (en) 2006-11-09
DK2426141T3 (da) 2014-11-10
US10350283B2 (en) 2019-07-16
EA012576B1 (ru) 2009-10-30
US20150231224A1 (en) 2015-08-20
IL215112A0 (en) 2011-10-31
ES2381492T3 (es) 2012-05-28
AU2006243357A1 (en) 2006-11-09
US9056913B2 (en) 2015-06-16
NO20141158L (no) 2008-01-25
SI2457926T1 (sl) 2015-01-30
CY1112851T1 (el) 2016-02-10
CN101273055B (zh) 2016-03-16
JP2008539187A (ja) 2008-11-13
NZ562729A (en) 2009-10-30
CN101273055A (zh) 2008-09-24
KR20120089475A (ko) 2012-08-10
NO20120381L (no) 2008-01-25
US20170196961A1 (en) 2017-07-13
BRPI0611347A2 (pt) 2010-08-31
US8470338B2 (en) 2013-06-25
WO2006117240A2 (en) 2006-11-09
NO345071B1 (no) 2020-09-14
JP5164830B2 (ja) 2013-03-21
IL186654A (en) 2013-04-30
EP1877426A2 (en) 2008-01-16
HRP20141184T1 (en) 2015-03-13
US9655958B2 (en) 2017-05-23
IL215112A (en) 2013-07-31
SI1877426T1 (sl) 2012-06-29
PT1877426E (pt) 2012-05-02
PL2457926T3 (pl) 2015-03-31
IL186654A0 (en) 2008-01-20
PT2457926E (pt) 2014-11-25
ES2524570T3 (es) 2014-12-10
JP2013040190A (ja) 2013-02-28
US10105430B2 (en) 2018-10-23
AU2006243357B2 (en) 2012-03-15
KR20080021624A (ko) 2008-03-07
PH12013502449A1 (en) 2015-12-14
EP2457926B1 (en) 2014-09-24
ATE543832T1 (de) 2012-02-15
CN102617739A (zh) 2012-08-01
EP2426141B1 (en) 2014-10-01
CA2607715C (en) 2015-11-24
US10639361B2 (en) 2020-05-05
SI2426141T1 (sl) 2015-01-30
PL1877426T3 (pl) 2012-10-31
DK1877426T3 (da) 2012-05-14

Similar Documents

Publication Publication Date Title
JP2008539187A5 (enExample)
ES2714383T3 (es) Vacuna TB contra la tuberculosis para impedir la reactivación
Villena et al. Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines
DK2270173T3 (en) Neisserial combination compositions
HRP20141125T1 (hr) Postupak sprjeäśavanja ili lijeäśenja infekcije bakterijom m. tuberculosis
Aagaard et al. TB vaccines: current status and future perspectives
Nadel Prospects for eradication of meningococcal disease
EP3134116B1 (en) New m.tuberculosis vaccines
JP2008543890A5 (enExample)
Flach et al. A truncated form of HpaA is a promising antigen for use in a vaccine against Helicobacter pylori
Osterloh The neglected challenge: Vaccination against rickettsiae
CN101745104A (zh) 含有复合佐剂的结核亚单位疫苗
Tanghe et al. Improved protective efficacy of a species-specific DNA vaccine encoding mycolyl-transferase Ag85A from Mycobacterium ulcerans by homologous protein boosting
Reed et al. Vaccines for parasitic and bacterial diseases
CN102488898B (zh) 龋齿疫苗及制备方法
Breiman et al. Vaccines to prevent respiratory infection: opportunities on the near and far horizon
US20110081382A1 (en) Treatment and prevention of tuberculosis
HRP20211256T1 (hr) Rekombinantni gen dgkk, namijenjen genskoj terapiji sindroma fragilnog kromosoma x
Ridelfi et al. State of the art and emerging technologies in vaccine design for respiratory pathogens
CN101883582B (zh) 激发一种对抗鸟分枝杆菌副结核亚种的免疫反应的合成物
Hovav et al. Pseudo-rationale design of efficient TB vaccines: lesson from the mycobacterial 27-kDa lipoprotein
JP4433147B2 (ja) レプトスピラ病に対する感染防御活性を有する薬剤
Miyazaki et al. Host immune responses to ribosome, ribosomal proteins, and RNA from Mycobacterium bovis bacille de Calmette–Gúerin
CA2598078A1 (en) Compositions for eliciting an immune response against mycobacterium avium subspecies paratuberculosis
Wilder-Smith The hajj pilgrimage: public health consequences of the largest people mass movement